The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
Abstract
BACKGROUND: Given the slow and variable clinical course of Alzheimer disease, very large and extended clinical trials are needed to identify a beneficial clinical effect of disease-modifying treatments. Therefore, biomarkers are essential to prove that an anti-β-amyloid (Aβ) drug candidate affects both Aβ metabolism and plaque load as well as downstream pathogenic mechanisms. OBJECTIVE: To evaluate the effect of the anti-Aβ monoclonal antibody bapineuzumab on cerebrospinal fluid (CSF) biomarkers reflecting Aβ homeostasis, neuronal degeneration, and tau-related pathology in patients with Alzheimer disease. DESIGN: Two phase 2, multicenter, randomized, double-blind, placebo-controlled clinical trials of 12-month duration. SETTING: Academic centers in the United States (Study 201) and England and Finland (Study 202). PATIENTS: Forty-six patients with mild to moderate Alzheimer disease. INTERVENTIONS: Patients received either placebo (n = 19) or bapineuzumab (n = 27) in 3 or 4 ascending dose groups. MAIN OUTCOME MEASURES: Changes between end of study and baseline in the exploratory CSF biomarkers Aβ1-42, AβX-42, AβX-40; total tau (T-tau); and phosphorylated tau (P-tau). RESULTS: Within the bapineuzumab group, a decrease at end of study compared with baseline was found both for CSF T-tau (-72.3 pg/mL) and P-tau (-9.9 pg/mL). When comparing the treatment and placebo groups, this difference was statistically significant for P-tau (P = .03), while a similar trend for a decrease was found for T-tau (P = .09). No clear-cut differences were observed for CSF Aβ. CONCLUSIONS: To our knowledge, this study is the first to show that passive Aβ immunotherapy with bapineuzumab results in decreases in CSF T-tau and P-tau, which may indicate downstream effects on the degenerative process. Cerebrospinal fluid biomarkers may be useful to monitor the effects of novel disease-modifying anti-Aβ drugs in clinical trials. TRIAL REGISTRATIONS clinicaltrials.gov Identifier: NCT00112073, EudraCT Identifier: 2004-004120-12, and isrctn.org Identifier: ISRCTN17517446.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In phase 2 clinical studies involving patients with mild-to-moderate Alzheimer’s disease, patients who received bapineuzumab, as compared with those who received placebo, had a greater reduction in amyloid on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and reduced cerebrospinal fluid phosphorylated tau (phospho-tau), suggesting target engagement”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [9]
In the citing paper
“In phase 2 clinical studies involving patients with mild-to-moderate Alzheimer’s disease, patients who received bapineuzumab, as compared with those who received placebo, had a greater reduction in amyloid on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and reduced cerebrospinal fluid phosphorylated tau (phospho-tau), suggesting target engagement”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [9]
In the citing paper
“in phase II trials, the anti-Aβ antibody bapineuzumab reduced CSF phospho-tau levels in patients with AD182,183”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [182]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Pathological verification of ischemic score in differentiation of dementias
Rosen, W. G., Terry, R. D., Fuld, P. A., Katzman, R., & Peck, A. (1980) · Annals of Neurology · doi:10.1002/ana.410070516 · Cited by 1,273
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–235 of 235
Clinical Issues in Alzheimer Drug Development
Schneider, L. S. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00019-8 · Cited by 1
Translational Research: Preclinical to Healthy Volunteer to Patient
Tammara, B. K., Raje, S. V., McKeand, W. E., & Korth-Bradley, J. M. (2017) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-50042-3_11 · Cited by 1
New Perspectives for Treatment in Alzheimer’s Disease
Loureiro, J. C., Silva, L. F. D. A. L. E., Pais, M. V., & Forlenza, O. V. (2022) · Springer eBooks · doi:10.1007/978-3-030-94383-7_10 · Cited by 1
Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
Pedrini, S., Morici, M., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch14 · Cited by 1
Graber, D. J., & Hickey, W. F. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1071-7_26 · Cited by 1
Synapses, spines, zinc and pathology of Alzheimer's disease.
Familtsev, D. (2013) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/420 · Cited by 1
Cognitive Enhancers and Treatments for Alzheimer's Disease
Devanand, D. P. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch109
CSF biomarkers could be used in Aβ immunotherapy trials for AD
Ozerlat, I. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.86
Markers of Prognosis in Neurodegenerative Dementia
Stubendorff, K. (2014) · Lund University Publications (Lund University)
Pouedras, C. (2013)
Antikörper bremst Hirndegeneration bei Morbus Alzheimer
Müller, T. M. (2012) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-012-0203-2
Immunotherapeutic Approaches Against Amyloid-β in Drug Discovery for Alzheimer’s Disease
Yang, S., Kim, J., & Kim, Y. S. (2015) · Springer eBooks · doi:10.1007/978-4-431-55763-0_22
Fluid Biomarkers and Diagnostics
Zetterberg, H., & Blennow, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00021-6
Self-citationImmunotherapy Against Amyloid-β Protofibrils: Opportunities and Challenges
Lannfelt, L. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_4
Tropea, T. F., & Henchcliffe, C. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107284210.024
Clinical Trials in Parkinson's Diease: Lessons, Controversies and Challenges
(2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107284210.022
Approach for Alzheimer's Disease
Tian, H. (2014)
Immunotherapy for the Treatment of Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00009-4
Modern approach in the therapy of Alzheimer's disease
Rodin, D., Schwarzman, A. L., & Saranzeva, S. V. (2014) · The Scientific Notes of the Pavlov University · doi:10.24884/1607-4181-2014-21-1-6-10
Pinheiro, N. R. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2018.tde-25042018-112913
Begcevic, I. (2018) · TSpace (University of Toronto)
Genomics of Alzheimer’s disease
Rosenberg, R. N., Lambracht‐Washington, D., Yu, G., & Xia, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00001-1
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
Mattsson, N., & Zetterberg, H. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6380-0_9
Self-citationDevelopment of Fluid Biomarkers for Alzheimer’s Disease
Blennow, K. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.033
Malik, N., Miah, M.-U., Galgani, A., McAleese, K. E., Walker, L., LeBeau, F. E. N., Attems, J., Outeiro, T. F., Thomas, A. J., & Koss, D. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.27.559720
Genomics of Alzheimer’s disease
Rosenberg, R. N., Lambracht‐Washington, D., Yu, G., & Xia, W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00035-2
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J. M., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M. P., Koyama, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14444875
Additional file 2 of Early detection of amyloid load using 18F-florbetaben PET
Bullich, S., Roé-Vellvé, N., Marquié, M., Landau, S. M., Barthel, H., Villemagne, V. L., Sanabria, Á., Tartari, J. P., Sotolongo‐Grau, Ó., Doré, V., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14330658
Additional file 1 of Early detection of amyloid load using 18F-florbetaben PET
Bullich, S., Roé-Vellvé, N., Marquié, M., Landau, S. M., Barthel, H., Villemagne, V. L., Sanabria, Á., Tartari, J. P., Sotolongo‐Grau, Ó., Doré, V., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14330655
Tau physiology and pathology: impacts on cellular structures and neurodegenerative diseases
Akbari, V., & Bahramikia, S. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02328-w
Halabian, N., Park, C., Omoto, L., Bocca, L. F., Ramos-Palacios, G., Wu, K., Hamani, C., Rabin, J. S., Abrahão, A., Davidson, B., et al. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.07.008
2014 — ein Schaltjahr für die Neurologie
Klein, F. (2014) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-014-0946-z
Metadata
- Authors
- Zetterberg, H.
- Affiliations
- University of Gothenburg (SE)
- Corresponding author
- Zetterberg, Henrik
- ORCID
- Zetterberg, Henrik
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2012-08-01
- Volume
- 69
- Issue
- 8
- Pages
- 1002
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2004535959
- Cited by
- 234
- References
- 29
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 5 · 2023: 9 · 2022: 8 · 2021: 12 · 2020: 10 · 2019: 4 · 2018: 16 · 2017: 12 · 2016: 24 · 2015: 25 · 2014: 44 · 2013: 39 · 2012: 18
- FWCI
- 27.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- bapineuzumab, Alzheimer's disease, cerebrospinal fluid biomarkers, anti-amyloid monoclonal antibodies, passive immunotherapy, amyloid-beta, tau phosphorylation, total tau, amyloid-beta 42, Aβ40, disease-modifying therapy, neurodegeneration, amyloid plaques
- MeSH terms
- Aged, Alzheimer Disease, Double-Blind Method, England, Female, Finland, Humans, Immunotherapy, Male, Middle Aged, Peptide Fragments, United States, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Outcome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
